GMRx2
Hypertension
Phase 3Active
Key Facts
About George Medicines
George Medicines is a venture-backed, private biotech company founded in 2018 as a spin-out from George Health and The George Institute for Global Health. It employs a de-risked, late-stage development model by creating single-pill combinations of approved drugs, with its lead program, GMRx2 for hypertension, in Phase 3 and actively securing global commercialization partnerships. The company's strategy is to accelerate time-to-market for therapies that address leading causes of death like hypertension and diabetes, focusing on both developed and developing world markets through a partnership-driven commercial approach.
View full company profileTherapeutic Areas
Other Hypertension Drugs
| Drug | Company | Phase |
|---|---|---|
| Valsartan EP Impurity B | Synthink Research Chemicals | Reference Standard |
| Norliqva® (Amlodipine Oral Solution) | CMP Pharma | Approved |
| Renal & Hepatic Denervation for Hypertension | Metavention | Feasibility |
| MVD-1 (SANA) | Eolo Pharma | Discovery |
| Peregrine System Renal Denervation | Ablative Solutions | Phase 3 |
| Hypertension Program | Closed Loop Medicine | Development |
| High Blood Pressure Study | West Coast Research | Phase 3/4 |
| Biobeat Cuff‑less ABPM Patch | Biobeat | Commercial |
| Zilebesiran (ALN-AGT) | Alnylam Pharmaceuticals | Phase 3 |
| DehydraTECH-CBD | Lexaria Bioscience | Human Clinical |